Search Results

There are 5068 results for: content related to: Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease

  1. Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules

    The Journal of Clinical Pharmacology

    Volume 47, Issue 10, October 2007, Pages: 1256–1267, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007304779

  2. You have free access to this content
    Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids

    British Journal of Clinical Pharmacology

    Volume 47, Issue 3, March 1999, Pages: 249–254, Kari Laine, Markku Anttila, Antti Helminen, Hari Karnani and Risto Huupponen

    Version of Record online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00891.x

  3. You have free access to this content
    Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline

    British Journal of Pharmacology

    Volume 143, Issue 3, October 2004, Pages: 371–378, Zaid A Abassi, Ofer Binah and Moussa B H Youdim

    Version of Record online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705962

  4. Selegiline for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline Birks and Leon Flicker

    Published Online : 20 JAN 2003, DOI: 10.1002/14651858.CD000442

  5. Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 146–158, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006296151

  6. Monoamine oxidase B inhibitors for early Parkinson's disease

    Intervention Review

    The Cochrane Library

    Kristian Turnbull, Robert Caslake, Angus Macleod, Natalie Ives, Rebecca Stowe and Carl Counsell

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD004898.pub2

  7. You have free access to this content
    Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat

    British Journal of Pharmacology

    Volume 149, Issue 6, November 2006, Pages: 647–656, J P M Finberg, A Gross, O Bar-Am, R Friedman, Y Loboda and M B H Youdim

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0706908

  8. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study

    Movement Disorders

    Volume 19, Issue 4, April 2004, Pages: 426–432, Cheryl H. Waters, Kapil D. Sethi, Robert A. Hauser, Eric Molho and John M. Bertoni

    Version of Record online : 10 FEB 2004, DOI: 10.1002/mds.20036

  9. Marked Effect of Liver and Kidney Function on the Pharmacokinetics of Selegiline

    Clinical Pharmacology & Therapeutics

    Volume 77, Issue 1, January 2005, Pages: 54–62, Markku Anttila, Eero A. Sotaniemi, Olavi Pelkonen and Arja Rautio

    Version of Record online : 16 JAN 2005, DOI: 10.1016/j.clpt.2004.09.004

  10. You have free access to this content
    Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo

    British Journal of Pharmacology

    Volume 126, Issue 4, February 1999, Pages: 997–1002, Itschak Lamensdorf, Shai Porat, Rabi Simantov and John P M Finberg

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0702389

  11. Changes in vascular alpha1- and alpha2-adrenoceptor responsiveness by selegiline treatment

    Fundamental & Clinical Pharmacology

    Volume 15, Issue 4, August 2001, Pages: 239–245, M. Pelat, P. Verwaerde, M. A. Tran, M. Berlan, J. M. Senard and J. L. Montastruc

    Version of Record online : 7 JUL 2008, DOI: 10.1046/j.1472-8206.2001.00036.x

  12. You have free access to this content
    Neuroprotective actions of selegiline

    Journal of Neuroscience Research

    Volume 67, Issue 3, 1 February 2002, Pages: 285–289, M. Ebadi, S. Sharma, S. Shavali and H. El Refaey

    Version of Record online : 7 JAN 2002, DOI: 10.1002/jnr.10148

  13. Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 8, August 2006, Pages: 933–944, Dr Albert J. Azzaro, Dr Chad M. VanDenBerg, Dr Lawrence F. Blob, Ms Eva M. Kemper, Dr Melvin Sharoky, Dr Dan A. Oren and Dr Bryan J. Campbell

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006289852

  14. You have free access to this content
    Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man

    British Journal of Clinical Pharmacology

    Volume 45, Issue 6, June 1998, Pages: 551–558, P. Bitsios, R. W. Langley, S Tavernor, K. Pyykkö, M. Scheinin, E. Szabadi and C. M. Bradshaw

    Version of Record online : 4 JAN 2002, DOI: 10.1046/j.1365-2125.1998.00729.x

  15. Effects of combined treatment with clorgyline and selegiline on extracellular noradrenaline and serotonin levels

    Acta Neuropsychiatrica

    Volume 24, Issue 6, December 2012, Pages: 369–373, Yuji Kitaichi, Takeshi Inoue, Shin Nakagawa, Shuken Boku and Tsukasa Koyama

    Version of Record online : 12 MAR 2012, DOI: 10.1111/j.1601-5215.2012.00652.x

  16. Evaluation of the Potential for Pharmacodynamic and Pharmacokinetic Drug Interactions Between Selegiline Transdermal System and Two Sympathomimetic Agents (Pseudoephedrine and Phenylpropanolamine) in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 47, Issue 8, August 2007, Pages: 978–990, Dr. Albert J. Azzaro, Dr. Chad M. VanDenBerg, Dr. John Ziemniak, Ms Eva M. Kemper, Dr. Lawrence F. Blob and Dr. Bryan J. Campbell

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007302950

  17. Cardiopulmonary effects of medetomidine, oxymorphone, or butorphanol in selegiline-treated dogs

    Veterinary Anaesthesia and Analgesia

    Volume 31, Issue 2, April 2004, Pages: 129–137, John R Dodam, Leah A Cohn, Harris E Durham and Balazs Szladovits

    Version of Record online : 29 MAR 2004, DOI: 10.1111/j.1467-2987.2004.00164.x

  18. Selegiline and blood pressure in patients with Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 115, Issue 2, February 2007, Pages: 104–108, V. Pursiainen, T. J. Korpelainen, H. T. Haapaniemi, A. K. Sotaniemi and V. V. Myllylä

    Version of Record online : 16 OCT 2006, DOI: 10.1111/j.1600-0404.2006.00742.x

  19. You have free access to this content
    Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

    Journal of Neurochemistry

    Volume 105, Issue 5, June 2008, Pages: 1970–1978, Wen Zhu, Wenjie Xie, Tianhong Pan, Joseph Jankovic, Jun Li, Moussa B. H. Youdim and Weidong Le

    Version of Record online : 8 MAR 2008, DOI: 10.1111/j.1471-4159.2008.05330.x

  20. You have free access to this content
    Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition

    The Journal of Physiology

    Volume 592, Issue 22, 15 November 2014, Pages: 4951–4968, Bo-Eun Yoon, Junsung Woo, Ye-Eun Chun, Heejung Chun, Seonmi Jo, Jin Young Bae, Heeyoung An, Joo Ok Min, Soo-Jin Oh, Kyung-Seok Han, Hye Yun Kim, Taekeun Kim, Young Soo Kim, Yong Chul Bae and C. Justin Lee

    Version of Record online : 21 OCT 2014, DOI: 10.1113/jphysiol.2014.278754